CHANGE TO ASTRAZENECA BOARD OF DIRECTORS

28 September 2016 07:00

CHANGE TO ASTRAZENECA BOARD OF DIRECTORS

AstraZeneca today announced that Dr Cornelia (Cori) Bargmann, a Non-Executive Director, will step down from the Board of AstraZeneca PLC and as a member of the Company's Science Committee with effect from 1 October 2016.  Dr Bargmann recently accepted a new position as President of Chan Zuckerberg Science, part of the Chan Zuckerberg Initiative.

Leif Johansson, AstraZeneca Chairman, said:  "We congratulate Cori on her new appointment and thank her for her contribution to AstraZeneca in the last 18 months.  We are sorry to see her leave the AstraZeneca Board but fully understand her decision to step down to focus on her new assignment."

About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The Company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com    

CONTACTS

Adrian Kemp
Company Secretary
AstraZeneca PLC

-ENDS-